These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 26256967)

  • 1. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
    Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
    J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
    Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
    Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H; Rashid S; Fazio S
    Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
    Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
    Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
    Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
    PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
    Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
    Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
    J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9: an emerging target for treatment of hypercholesterolemia.
    Duff CJ; Hooper NM
    Expert Opin Ther Targets; 2011 Feb; 15(2):157-68. PubMed ID: 21204732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.